Evaluation of the criteria for renewal of LHRH agonists in patients with prostate cancer: results of the ANAREN Study

• Published in: Drugs in Context 2024-06, Vol.13 (13), p.1-12
• Main Authors: Calleja-Escudero, Jesús, Barrondo, Víctor, Rodriguez-Alonso, Andrés, Gómez-Veiga, Francisco, Bestard, Joan, Gómez-Caamaño, Antonio, Grandoulier, Anne-Sophie, Pérez-Sampietro, Maria, Chantada-Abal, Venancio, Poza de Celis, Raúl
• Format: Article
• Language: English
• Subjects: androgen deprivation; concomitant; hormone therapy; Original Research; quality of life; radiotherapy
• ISSN: 1745-1981; 1740-4398
• DOI: 10.7573/dic.2024-2-2

Injectable extended-release formulations of luteinizing hormone-releasing hormone agonists (LHRHa) have simplified the treatment of prostate cancer with a satisfactory level of androgen castration. This study aims to determine the percentage of patients whose initial LHRHa prescription was renewed during follow-up, how many changed formulation and how their quality of life evolved. This is an observational, prospective, multicentre study of men with prostate cancer who were to receive treatment with LHRHa (triptorelin every 3 or 6 months, leuprorelin every 3 or 6 months, or goserelin every 3 months) for 24 months. The treatment used was recorded and quality of life was assessed (QLQ-PR25 questionnaire) at four follow-up visits. A total of 497 men (median age 75 years) were evaluated. The median exposure to LHRHa was 24 months. The initial prescription was renewed in 95.7% at follow-up 1 and 75% at follow-up 4. The main reason for changing from a 6-month to a 3-month formulation was a preference for sequential treatment (according to the investigator) and to see the physician more frequently (according to the patient). The main reason for switching from the 3-month to 6-month formulation was simplification of treatment (according to the investigator) and for convenience (according to the patient). Findings in the QLQ-PR25 questionnaire revealed no changes in urinary or bowel symptoms, though an improvement in sexual activity was reported. Practically all investigators and patients were satisfied/very satisfied with the treatment. Changes in formulation were scarce and generally justified by convenience factors or personal preferences. Patients maintained a good health status, with a high rate of retention of LHRHa treatment. Study number: A-ES-52014-224.A plain language summary is provided as supplementary material (available at: https://www.drugsincontext.com/wp-content/uploads/2024/05/dic.2024-2-2-Suppl.pdf).